Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
Annual EBITDA margin expands by 170 basis points
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Akums invested Rs. 272 crore in capital expenditure during FY25
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Subscribe To Our Newsletter & Stay Updated
